Cannabis Genetics Research Advances Cannabinoid Profiles for Medical Use
Cannabis genetics research by Dr. Zacariah Hildenbrand and Adam Jacques advances cannabinoid profiles, offering new hope for medical treatments
Key Points
- 1Cannabis genetics significantly influence cannabinoid profiles, aiding medical research
- 2Research focuses on rare cannabinoids like THCV and CBC for disease treatment
- 3Epigenetics and environmental factors play crucial roles in cannabinoid production
- 4Selective breeding has increased CBC levels in cannabis plants for neuroprotection
- 5Significant potential remains for further discoveries in cannabis genetic research
Recent discussions between Dr. Zacariah Hildenbrand and geneticist Adam Jacques have highlighted the significant influence of cannabis genetics on cannabinoid profiles, with promising implications for medical applications. Their research underscores the potential for developing cannabis strains with enhanced levels of rare cannabinoids like THCV and CBC, which could aid in treating conditions such as metabolic syndrome and neurodegenerative diseases
Dr. Hildenbrand, a partner at Medusa Analytical, and Jacques, from Big Earth Consulting, are pushing the boundaries of cannabis genetics to explore the effects of various cannabinoids beyond the well-known THC and CBD. Their focus includes the minor cannabinoid CBC, which has shown potential as a neuroprotective agent, potentially benefiting patients with Alzheimer's and Parkinson's diseases. By manipulating genetic factors, they aim to create novel medicinal strains with higher concentrations of these beneficial compounds
The researchers emphasize the role of epigenetics in cannabis cultivation, where environmental conditions can affect genetic expression in plants. Hildenbrand notes that factors such as soil quality, light, and water can significantly influence the cannabinoid output of cannabis plants. This understanding allows them to refine cultivation techniques to maximize the presence of desired cannabinoids in subsequent plant generations
Adam Jacques shares a personal connection to the research, motivated by his family's history with Alzheimer's disease. His work has led to a substantial increase in CBC levels in cannabis plants, from less than 1% to over 3% through selective breeding techniques. This progress exemplifies how targeted genetic manipulation can yield strains with enhanced therapeutic properties, offering hope for more effective treatments for neurodegenerative conditions
Despite the progress, Hildenbrand and Jacques acknowledge that the field of cannabis genetics is still in its infancy. They believe that there is vast potential for further discoveries, as the biopharmaceutical industry has yet to fully capitalize on the opportunities within cannabis research. As they continue their work, the researchers remain optimistic about uncovering new cannabinoid profiles that could revolutionize medical treatments